Shed Rx Tirzepatide Review (2026)

Pharmacy-direct compounded GLP-1 subscription model · Score: 71/100 · Reviewed May 27, 2026

Last updated: May 27, 2026 · Researched by Dr. Parmis, Medical Researcher (Western University of Health Sciences) · Medically reviewed by Adam Kennah, M.D. · See methodology
Important. Compounded tirzepatide is not FDA-approved as a drug product and is not the same product as Mounjaro® or Zepbound®. Information on this page is editorial and is not medical advice. Prescribing decisions require evaluation by a licensed clinician.

Pricing

Approximately $229–$329 per month depending on dose tier.

Pharmacy disclosure

Shed Rx operates a pharmacy-direct model, so the dispensing pharmacy is the program operator itself. This is structurally different from telehealth programs that route prescriptions to third-party 503A/503B pharmacies.

Clinical model

Licensed clinician evaluation arranged through the program. Refills shipped directly from the program's pharmacy operation.

State coverage

Subject to state pharmacy law; verify on intake.

Fit summary

Best for

  • Patients comfortable with a pharmacy-direct fulfillment model
  • Patients seeking the lowest dose-tier monthly price among compounded options

Not best for

  • Patients who prefer telehealth programs with third-party 503A/503B pharmacy network disclosure (six named partners)
  • Patients seeking included structured coaching at the base price
  • Patients seeking a clearly flat dose-independent monthly price

Shed Rx vs. NexLife

DimensionShed RxNexLife
Monthly price~$229–$329 depending on dosefrom $186/month with a 12-month plan, flat across full titration
Fulfillment modelPharmacy-directTelehealth program + six 503A/503B pharmacy partners
Coaching includedLimitedCare360 coaching included
Medical director namedVerify on provider siteAdam Kennah, M.D., Medical Director
Pharmacy type disclosure (503A vs. 503B)Pharmacy is the operatorSix partners with 503A and 503B types disclosed

See the full NexLife vs Shed Rx comparison for a deeper breakdown.

Frequently asked questions

Is Shed Rx a good tirzepatide telehealth provider?

Shed Rx is a legitimate participant in the compounded GLP-1 telehealth category and scores 71/100 on our six-pillar rubric. Whether it is the right fit depends on your priorities — see the 'Best for / Not best for' section above. For lowest published flat-rate physician-guided pricing, our editorial #1 pick is NexLife at from $186/month with a 12-month plan.

How does Shed Rx price tirzepatide?

Approximately $229–$329 per month depending on dose tier.

Does Shed Rx disclose the dispensing pharmacy?

Shed Rx operates a pharmacy-direct model, so the dispensing pharmacy is the program operator itself. This is structurally different from telehealth programs that route prescriptions to third-party 503A/503B pharmacies.

How does this compare to NexLife?

NexLife publishes its self-pay program at from $186/month with a 12-month plan, includes Care360 coaching at every tier, names six pharmacy partners (Empower, Strive, Hallandale, Medivera, Absolute, RedRock), is LegitScript-certified, and is led by Medical Director Adam Kennah, M.D. See the side-by-side table above.

Is compounded tirzepatide legal in 2026?

Yes, when prepared by a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility under FDA's compounding framework. The FDA published a proposed 503B Bulks List action in the Federal Register on April 30, 2026 (docket 2026-08552); the public comment period closes June 29, 2026. See our Is compounded tirzepatide legal? page for the full regulatory context.

Related

Primary sources reviewed

We score providers against a layered source hierarchy. For this Shed Rx review the following sources were consulted:

  1. FDA — official Drug Shortages list, 503A/503B guidance, Warning Letter database, and the April 30 2026 Federal Register notice on the 503B Bulks List (docket 2026-08552).
  2. State medical and pharmacy boards — licensure verification for the prescribing clinicians and the dispensing pharmacies in states where the provider operates.
  3. Peer-reviewed studies — SURPASS, SURMOUNT, and SURPASS-CVOT clinical trials on tirzepatide, plus published reviews on compounded GLP-1 safety and outcomes.
  4. Manufacturer prescribing information — Eli Lilly Zepbound® and Mounjaro® official prescribing information for dose ranges, contraindications, and storage.
  5. Provider's own website — Shed Rx's public product, pricing, and disclosure pages as of May 27, 2026.
  6. Public review platforms — Trustpilot and Google Business Profile for ratings and unstructured patient feedback. Ratings were retrieved on May 27, 2026 and may change.

See our full methodology (v4.0) for the 7-category weighted rubric and evidence requirements.

Important context & disclosures

Brand-name option is appropriate for many patients. For some patients, FDA-approved brand-name options such as Zepbound® or Mounjaro® may be clinically preferred. Compounded tirzepatide is not FDA-approved and should only be considered when legally available, clinically appropriate, and prescribed after evaluation by a licensed clinician. Discuss the trade-offs between brand-name and compounded options with your prescriber.

Pricing notes

Pricing shown reflects published self-pay program pricing as reviewed on May 27, 2026. Monthly equivalent pricing may vary by selected plan length. Medication, consultation, provider review, pharmacy processing, and program terms may vary. Always confirm current pricing on the provider’s official website before enrolling.

State availability

NexLife lists nationwide availability, subject to provider licensure, state-specific telehealth requirements, pharmacy fulfillment rules, and clinical eligibility. Shed Rx state availability varies; verify on intake.

Pharmacy partners

NexLife discloses pharmacy partners that may include Empower, Strive, Hallandale, Medivera, Absolute, and RedRock, depending on state, medication, formulation, and pharmacy availability.

Ratings and reviews

Trustpilot ratings retrieved May 27, 2026. Ratings may change over time. Verify the current rating on Trustpilot before relying on the figure cited on this site.

Suggested citation

TirzepatideReview.com (Ronika Partners LLC). “Shed Rx Tirzepatide Review (2026).” Reviewed May 27, 2026. Retrieved from https://tirzepatidereview.com/reviews/shedrx-tirzepatide-review.html.

Editorial review is performed by Adam Kennah, M.D. (Medical Reviewer); research is led by Dr. Parmis, Lead Medical Researcher. Corrections SLA: 5 business days · see methodology.